MYndspan Receives Strategic Investment from Emotiv
Summary
MYndspan, a London, UK-based company offering clinical-grade MEG brain scanning to consumers, received a strategic investment from EMOTIV, a global leader in neurotechnology and wearable EEG.EMOTIV joined as a key backer in MYndspans crowd funding campaign.Led by Caitlin Baltzer, Co-Founder and CEO, MYndspan aims to improve access to preventive and proactive brain health. It is developing non-invasive Magnetoencephalography (MEG) technology directly to the consumer.The MEG scans generate insights like Functional Brain Age and the Brain Stability Index, markers designed to detect signs of neurodegeneration, cognitive fog, and injury years before symptoms emerge. By correlating these biomarkers with EEG signals, MYndspan and EMOTIV can bring this clinical insight to the wearable market, enabling smarter, more personalized neurotechnological interventions.This partnership connects MYndspans clinical-grade MEG assessments with EMOTIVs real-time EEG technology, bridging the gap between clinical brain insights and everyday brain tracking, making it easier for individuals and clinicians to access continuous, meaningful data to support proactive brain health.EMOTIVs consumer technology includes the Emotiv App and MN8 earbuds, AI-powered tools that deliver continuous, real-time insights into users cognitive states such as focus, stress, and mental fitness. These wearable EEG tools are already used by thousands to optimize mental performance, and now, by integrating MYndspans MEG-derived biomarkers, EMOTIV can provide even more accurate, longitudinal brain health insights.